semaglutide and smoking cigarettes (Ozempic) found to treat addiction Demand for weight loss drugs

Article Summary: GLP1s and GIP dual agonists like Mounjaro and Wegovy are once-weekly injections prescribed for weight loss and type 2 diabetes

Over 41% of American adults struggle with obesity, yet access to GLP-1 receptor agonists remains limited by insurance barriers and cost

Here's what we'll cover Here's what we'll cover Here's what we'll cover Key takeaways Tirzepatide and semaglutide are GLP-1 medications available for weight loss under the brand names Zepbound and Wegovy

Common gastrointestinal effects (affecting more than 1 in 10 people) include nausea, diarrhoea, and vomiting, particularly during the initial weeks of treatment or following dose increases

To get a covered drug, your provider submits a prior authorization request and prescription to the CMS central processor

This emerging area of study highlights the broader role that GLP-1 could play in addiction treatment